{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:48Z","timestamp":1787841288487,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004035","name":"Jordan University of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE\/BACKGROUND:<\/jats:title>\n                    <jats:p>\n                      Myeloproliferative neoplasms (MPNs) are heterogeneous clonal bone marrow stem cell disorders and include polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF) neoplasia. In 2005, the\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      <jats:sup>V617F<\/jats:sup>\n                      mutation was identified in Philadelphia chromosome-negative patients. The aim of this study was to sequence coding exons 12 and 14 of the\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      gene in Jordanian patients with MPN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Both exons 12 and 14 of the JAK2 gene were amplified using polymerase chain reaction from DNA extracted from 68 blood and bone marrow samples belonging to 57 MPN patients and subjected to DNA sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      <jats:sup>V617F<\/jats:sup>\n                      mutations were detected in 26 of 57 Jordanian patients (45%) with different MPNs.\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      <jats:sup>V617F<\/jats:sup>\n                      was identified in 70%, 31%, and 14% of PV, ET, and IMF cases, respectively. Five men diagnosed with PV were homozygous for\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      <jats:sup>V617F<\/jats:sup>\n                      , whereas the other 21 patients were heterozygous for the mutation. Neither the\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      <jats:sup>V617F<\/jats:sup>\n                      mutation nor any DNA polymorphism in exon 12 or exon 14 of the\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      gene was detected among the 40 leukemic patients. A rare single nucleotide polymorphism, c.1860C\u2192T (rs375442615), was detected in one patient with ET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>\n                      This study is the first molecular investigation of the\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      gene in Jordan. We successfully identified the\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      <jats:sup>V617F<\/jats:sup>\n                      mutation in Jordanian patients with Philadelphia chromosome-negative MPNs. Our results provide a basis for the early detection of this mutation and simplify the diagnostic workup for these disorders at the molecular level.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2015.07.004","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T10:07:19Z","timestamp":1438596439000},"page":"160-166","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of JAK2 V617F mutation in Jordanian patients with myeloproliferative neoplasms"],"prefix":"10.4103","volume":"8","author":[{"given":"Saied A","family":"Jaradat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Khasawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazmi","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Matalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Bishtawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleiman","family":"Al-Sweedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud H","family":"Ayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2015.07.004_b0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0010","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2015.07.004_b0015","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2015.07.004_b0025","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.hemonc.2015.07.004_b0030","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2015.07.004_b0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hemonc.2015.07.004_b0040","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1128\/MCB.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.hemonc.2015.07.004_b0045","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2015.07.004_b0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2353\/jmoldx.2009.080114","article-title":"Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias","volume":"11","author":"Ma","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.hemonc.2015.07.004_b0060","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.hemonc.2015.07.004_b0065","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2015.07.004_b0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.hemonc.2015.07.004_b0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.hemonc.2015.07.004_b0080","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2015.07.004_b0085","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2015.07.004_b0095","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.07.004_b0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/gtmb.2010.0136","article-title":"JAK2V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon","volume":"15","author":"Mahfouz","year":"2011","journal-title":"Genet Test Mol Biomarkers"},{"issue":"1\u20132","key":"10.1016\/j.hemonc.2015.07.004_b0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/gtmb.2010.0093","article-title":"Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders","volume":"15","author":"Ayad","year":"2011","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.hemonc.2015.07.004_b0110","series-title":"World Health Organization classification of tumours. Pathology and genetics: tumours of hematopoietic and lymphoid tissues","first-page":"32","article-title":"Polycythemia vera","author":"Pierre","year":"2001"},{"key":"10.1016\/j.hemonc.2015.07.004_b0115","series-title":"World Health Organization classification of tumours. Pathology and genetics: tumours of hematopoietic and lymphoid tissues","first-page":"39","article-title":"Essential thrombocythemia","author":"Imbert","year":"2001"},{"key":"10.1016\/j.hemonc.2015.07.004_b0120","series-title":"World Health Organization classification of tumours. Pathology and genetics: tumours of hematopoietic and lymphoid tissues","first-page":"35","article-title":"Chronic idiopathic myelofibrosis","author":"Thiele","year":"2001"},{"key":"10.1016\/j.hemonc.2015.07.004_b0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.20721","article-title":"Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera","volume":"82","author":"Ganly","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2015.07.004_b0130","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hemonc.2015.07.004_b0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.leu.2404861","article-title":"Quantitative assessment of the JAK2V617F allele burden: equivalent levels in peripheral blood and bone marrow","volume":"22","author":"Larsen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2015.07.004_b0140","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0145","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404419","article-title":"Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera","volume":"20","author":"Gr\u00fcnebach","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2015.07.004_b0150","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.07.004_b0155","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s002770050546","article-title":"Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders\u2014aids to diagnosis and classification","volume":"78","author":"Thiele","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hemonc.2015.07.004_b0165","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0170","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2015.07.004_b0175","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387615000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387615000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201508040-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:25Z","timestamp":1787838505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201508040-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2015.07.004","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}